Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ARTHNASDAQ:ELGXNASDAQ:PAVMNASDAQ:SNWV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTHArch Therapeutics$0.12$0.16▼$1.57$763K4.024,068 shsN/AELGXEndologix$0.07$0.03$0.22▼$7.10$1.41M0.731.28 million shs85,372 shsPAVMPAVmed$0.60+1.0%$0.65$0.55▼$1.90$10.21M1.06136,075 shs19,874 shsSNWVSanuwave Health$31.65-0.2%$30.34$5.17▼$39.50$270.78M1.24145,744 shs21,863 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTHArch Therapeutics0.00%0.00%0.00%-99.33%-99.88%ELGXEndologix0.00%0.00%0.00%0.00%0.00%PAVMPAVmed0.00%-0.50%-5.46%+0.34%-15.68%SNWVSanuwave Health0.00%+5.68%+13.85%+3.20%+3,164,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTHArch TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AELGXEndologixN/AN/AN/AN/AN/AN/AN/AN/APAVMPAVmed3.9509 of 5 stars3.55.00.04.30.00.01.9SNWVSanuwave HealthN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTHArch Therapeutics 0.00N/AN/AN/AELGXEndologix 0.00N/AN/AN/APAVMPAVmed 3.00Buy$19.003,082.58% UpsideSNWVSanuwave Health 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SNWV, ARTH, PAVM, and ELGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025PAVMPAVmedAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.50 ➝ $19.004/21/2025PAVMPAVmedAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $19.50(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTHArch Therapeutics$80K0.00N/AN/A($2.43) per share0.00ELGXEndologix$143.37M0.01N/AN/A$3.56 per share0.02PAVMPAVmed$1.99M5.12N/AN/A($0.92) per share-0.65SNWVSanuwave Health$32.63M8.30N/AN/A($1.49) per share-21.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTHArch Therapeutics-$6.98MN/A0.00N/AN/A-8,257.70%N/A-730.22%8/18/2025 (Estimated)ELGXEndologix-$64.76M-$2.19N/AN/AN/A-44.65%-63.96%-13.26%N/APAVMPAVmed$39.79M$0.710.84N/AN/A3,711.54%N/A-42.29%8/12/2025 (Estimated)SNWVSanuwave Health-$31.37M-$4.56N/A∞N/A-89.86%N/A-145.76%N/ALatest SNWV, ARTH, PAVM, and ELGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025SNWVSanuwave HealthN/A-$0.66N/A-$0.66N/A$9.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTHArch TherapeuticsN/AN/AN/AN/AN/AELGXEndologixN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/ASNWVSanuwave HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTHArch TherapeuticsN/A0.100.01ELGXEndologix0.290.390.28PAVMPAVmedN/A0.370.37SNWVSanuwave HealthN/A0.400.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTHArch Therapeutics6.91%ELGXEndologix51.61%PAVMPAVmed19.93%SNWVSanuwave Health42.53%Insider OwnershipCompanyInsider OwnershipARTHArch Therapeutics4.50%ELGXEndologix1.30%PAVMPAVmed7.30%SNWVSanuwave Health36.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTHArch Therapeutics104.74 million4.53 millionNot OptionableELGXEndologix52819.17 millionN/AOptionablePAVMPAVmed9017.09 million15.85 millionOptionableSNWVSanuwave Health408.56 million5.43 millionN/ASNWV, ARTH, PAVM, and ELGX HeadlinesRecent News About These CompaniesSanuwave: High Growth Wound Care Tech Primed For A BreakoutJune 11, 2025 | seekingalpha.comSANUWAVE Health, Inc. (NASDAQ:SNWV) COO Sells $51,596.02 in StockJune 9, 2025 | marketbeat.comSanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial OperationsJune 3, 2025 | globenewswire.comSANUWAVE Health, Inc. (SNWV): A Bull Case TheoryMay 29, 2025 | insidermonkey.comSanuwave Health Appoints Greg Bazar to Board of DirectorsMay 28, 2025 | globenewswire.comSanuwave Health Selected for Inclusion in Russell 2000® IndexMay 28, 2025 | globenewswire.comInsider Selling: SANUWAVE Health, Inc. (NASDAQ:SNWV) Insider Sells 3,639 Shares of StockMay 17, 2025 | insidertrades.comSANUWAVE Health, Inc. (SNWV) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comSanuwave Announces Q1 FY2025 Financial ResultsMay 9, 2025 | globenewswire.comSanuwave Will Host a Conference Call on May 9, 2025 at 8:30 AM (ET) to Present Q1 2025 Financial ResultsMay 5, 2025 | globenewswire.comSANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)April 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeRocket Lab: Europe Comes Calling as Momentum BuildsBy Ryan Hasson | June 27, 2025View Rocket Lab: Europe Comes Calling as Momentum BuildsSNWV, ARTH, PAVM, and ELGX Company DescriptionsArch Therapeutics OTCMKTS:ARTHArch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.Endologix NASDAQ:ELGXEndologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.PAVmed NASDAQ:PAVM$0.60 +0.01 (+1.02%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$0.60 0.00 (0.00%) As of 07/3/2025 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.Sanuwave Health NASDAQ:SNWV$31.65 -0.07 (-0.22%) As of 07/3/2025 01:00 PM EasternSANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.